
    
      -  Participants on this study will receive cetuximab by infusion intravenously once per
           week and may continue to receive weekly cetuximab infusions until their disease
           progresses or they experience unacceptable side effects.

        -  The following will be performed every 4 weeks while they are receiving study treatments:
           Physical examination; performance status; and blood work. A CT scan of the chest and
           upper abdomen will be performed every 8 weeks.
    
  